[{"id":"656cee62-adb1-42af-aff2-01bcd8381617","acronym":"","url":"https://clinicaltrials.gov/study/NCT06529731","created_at":"2025-02-26T12:45:31.126Z","updated_at":"2025-02-26T12:45:31.126Z","phase":"Phase 2","brief_title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT06529731","lead_sponsor":"Sawa Ito, MD","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actimmune (interferon gamma-1 b)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-10-31"},{"id":"7fc864bc-2037-4926-9819-2552b751ef5d","acronym":"ATTAC-MCC","url":"https://clinicaltrials.gov/study/NCT03747484","created_at":"2021-06-30T14:53:31.876Z","updated_at":"2024-07-02T16:35:12.716Z","phase":"Phase 1/2","brief_title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","source_id_and_acronym":"NCT03747484 - ATTAC-MCC","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2025","study_completion_date":" 01/10/2025","last_update_posted":"2024-03-26"},{"id":"bb4e23f9-35f3-4dc9-bf65-0113130803e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628338","created_at":"2021-01-19T20:35:59.612Z","updated_at":"2024-07-02T16:35:27.774Z","phase":"Phase 1","brief_title":"IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT04628338","lead_sponsor":"Sawa Ito, MD","biomarkers":" ICAM1 • STAT1 • HLA-C","pipe":"","alterations":" ","tags":["ICAM1 • STAT1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/08/2021","start_date":" 03/08/2021","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-11-29"},{"id":"0ed959af-c2b5-458e-b542-28311d0168e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063632","created_at":"2021-01-18T15:05:12.923Z","updated_at":"2024-07-02T16:35:31.715Z","phase":"Phase 2","brief_title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","source_id_and_acronym":"NCT03063632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["IFNG • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-10-25"},{"id":"e0aa1019-5c4c-4207-8e73-64bc03119d37","acronym":"MCC-18936","url":"https://clinicaltrials.gov/study/NCT03112590","created_at":"2021-01-18T15:20:06.945Z","updated_at":"2025-02-25T13:52:18.507Z","phase":"Phase 1/2","brief_title":"Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT03112590 - MCC-18936","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 02/20/2023","study_completion_date":" 02/20/2023","last_update_posted":"2023-04-19"},{"id":"a613a9e1-5d66-4f16-986c-8d89ea344813","acronym":"","url":"https://clinicaltrials.gov/study/NCT02614456","created_at":"2021-01-18T12:42:08.108Z","updated_at":"2024-07-02T16:36:53.106Z","phase":"Phase 1","brief_title":"Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors","source_id_and_acronym":"NCT02614456","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/11/2015","start_date":" 12/11/2015","primary_txt":" Primary completion: 06/12/2019","primary_completion_date":" 06/12/2019","study_txt":" Completion: 06/12/2019","study_completion_date":" 06/12/2019","last_update_posted":"2019-11-29"},{"id":"0b6c1e9d-8ae3-4c5a-b112-08bf2b62faca","acronym":"TARGET-I","url":"https://clinicaltrials.gov/study/NCT02197169","created_at":"2021-01-18T10:16:26.540Z","updated_at":"2024-07-02T16:37:08.941Z","phase":"Phase 1b","brief_title":"DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors","source_id_and_acronym":"NCT02197169 - TARGET-I","lead_sponsor":"DNAtrix, Inc.","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401) • Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/11/2014","start_date":" 09/11/2014","primary_txt":" Primary completion: 03/15/2018","primary_completion_date":" 03/15/2018","study_txt":" Completion: 03/15/2018","study_completion_date":" 03/15/2018","last_update_posted":"2018-07-16"}]